论文部分内容阅读
1文献来源Ramalingam SS,Vansteenkiste J,Planchard D,et al.Overall survival with Osimertinib in untreated,EGFR-mutanted advanced NSCLC[J].N Engl J Med,2020,382(1):41-50.2证据水平1b。3背景伴随表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变,例如19号外显子缺失(Ex19 del)或21号外显子